SG11202010150PA - Monoclonal antibody of nerve growth factor and encoding gene and use thereof - Google Patents

Monoclonal antibody of nerve growth factor and encoding gene and use thereof

Info

Publication number
SG11202010150PA
SG11202010150PA SG11202010150PA SG11202010150PA SG11202010150PA SG 11202010150P A SG11202010150P A SG 11202010150PA SG 11202010150P A SG11202010150P A SG 11202010150PA SG 11202010150P A SG11202010150P A SG 11202010150PA SG 11202010150P A SG11202010150P A SG 11202010150PA
Authority
SG
Singapore
Prior art keywords
monoclonal antibody
growth factor
encoding gene
nerve growth
nerve
Prior art date
Application number
SG11202010150PA
Inventor
Zhongmin Maxwell Wang
Baiyong Li
Yu Xia
Peng Zhang
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Publication of SG11202010150PA publication Critical patent/SG11202010150PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
SG11202010150PA 2018-04-17 2019-04-10 Monoclonal antibody of nerve growth factor and encoding gene and use thereof SG11202010150PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810344670.3A CN108623687A (en) 2018-04-17 2018-04-17 The monoclonal antibody and its encoding gene of nerve growth factor and application
CN201811320006.1A CN109553683A (en) 2018-04-17 2018-11-07 The monoclonal antibody and its encoding gene of nerve growth factor and application
PCT/CN2019/082107 WO2019201133A1 (en) 2018-04-17 2019-04-10 Monoclonal antibody of nerve growth factor and encoding gene and use thereof

Publications (1)

Publication Number Publication Date
SG11202010150PA true SG11202010150PA (en) 2020-11-27

Family

ID=63705267

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010150PA SG11202010150PA (en) 2018-04-17 2019-04-10 Monoclonal antibody of nerve growth factor and encoding gene and use thereof

Country Status (15)

Country Link
US (2) US11680095B2 (en)
EP (1) EP3783021A4 (en)
JP (1) JP2021521881A (en)
KR (1) KR20200143471A (en)
CN (3) CN108623687A (en)
AU (1) AU2019254934A1 (en)
BR (1) BR112020021256A2 (en)
CA (1) CA3097414A1 (en)
EA (1) EA202092491A1 (en)
IL (1) IL277982A (en)
MX (1) MX2020010863A (en)
PH (1) PH12020551678A1 (en)
SG (1) SG11202010150PA (en)
WO (1) WO2019201133A1 (en)
ZA (1) ZA202006317B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623687A (en) * 2018-04-17 2018-10-09 中山康方生物医药有限公司 The monoclonal antibody and its encoding gene of nerve growth factor and application
CN110684106B (en) * 2019-09-30 2021-02-02 达石药业(广东)有限公司 Monoclonal antibody of targeted nerve growth factor and application thereof
CN117003868B (en) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
CN117050175A (en) * 2020-04-17 2023-11-14 珠海泰诺麦博制药股份有限公司 Antibodies against human nerve growth factor
CN113993900B (en) * 2020-05-27 2023-08-04 舒泰神（北京）生物制药股份有限公司 Antibodies specifically recognizing nerve growth factor and uses thereof
CN114470189B (en) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Application of NGF antibody in CIPN pain
CN113444176B (en) * 2021-06-02 2022-10-14 武汉人福创新药物研发中心有限公司 Antibodies to NGF and uses thereof
WO2023004784A1 (en) 2021-07-30 2023-02-02 成都优洛生物科技有限公司 Recombinant cho cell, construction method therefor, and detection system and method using same
CN116836276B (en) * 2023-07-28 2023-12-08 艾可泰科(浙江)控股有限公司 Stem cell preparation for repairing knee joint injury and preparation process thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT1575517E (en) * 2002-12-24 2012-05-28 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
AU2011201157C1 (en) * 2002-12-24 2017-09-07 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
NZ544751A (en) 2003-07-15 2009-05-31 Amgen Inc Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
AU2012201465A1 (en) * 2005-06-07 2012-04-05 Abbott Research B.V Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
ME00977B (en) * 2007-08-10 2012-06-20 Regeneron Pharma High affinity human antibodies to human nerve growth factor
UY32608A (en) * 2009-05-04 2010-12-31 Pangenetics 110 B V ANTIBODIES AGAINST THE NERVOUS GROWTH FACTOR (NGF) WITH IMPROVED LIVE STABILITY
AU2011336470B8 (en) * 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN104910274B (en) 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 The neutralizing monoclonal antibody 12C11 and its hybridoma cell strain of anti human nerve growth factor
CN108623687A (en) 2018-04-17 2018-10-09 中山康方生物医药有限公司 The monoclonal antibody and its encoding gene of nerve growth factor and application

Also Published As

Publication number Publication date
KR20200143471A (en) 2020-12-23
US20210155683A1 (en) 2021-05-27
BR112020021256A2 (en) 2021-02-02
ZA202006317B (en) 2024-01-31
WO2019201133A1 (en) 2019-10-24
CN112166121B (en) 2022-11-22
CA3097414A1 (en) 2019-10-24
EA202092491A1 (en) 2021-02-09
CN108623687A (en) 2018-10-09
IL277982A (en) 2020-11-30
PH12020551678A1 (en) 2021-06-07
EP3783021A4 (en) 2022-03-02
US20240025983A1 (en) 2024-01-25
CN112166121A (en) 2021-01-01
US11680095B2 (en) 2023-06-20
AU2019254934A1 (en) 2020-11-19
MX2020010863A (en) 2021-01-29
CN109553683A (en) 2019-04-02
EP3783021A1 (en) 2021-02-24
JP2021521881A (en) 2021-08-30

Similar Documents

Publication Publication Date Title
SG11202010150PA (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL279053A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
IL287282A (en) Anti-mertk antibodies and their methods of use
IL290741A (en) Anti-cd96 antibodies and methods of use thereof
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
IL277212A (en) Anti-klk5 antibodies and methods of use
IL289952A (en) Anti-ms4a4a antibodies and methods of use thereof
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL291461A (en) Anti-alpha-synuclein antibodies and methods of use thereof
IL282424A (en) Alk2 antibodies and methods of use thereof
EP4061847A4 (en) Anti-b7-h3 monoclonal antibody and methods of use thereof
EP4061848A4 (en) Anti-ror-2 antibodies and methods of use
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
IL273538A (en) Anti-trkb monoclonal antibodies and methods of use
IL288886A (en) Antibodies and methods of use
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof